At Courage Against Cancer (CAC), we believe patients deserve evidence-based answers to the pillar article’s primary question — not dismissal, and not hype. Oncologist caution around fenbendazole in 2026 is rooted in specific clinical and regulatory reasoning, not ignorance of the research.
